EA202192532A1 - Мирикизумаб для применения в способе лечения болезни крона - Google Patents

Мирикизумаб для применения в способе лечения болезни крона

Info

Publication number
EA202192532A1
EA202192532A1 EA202192532A EA202192532A EA202192532A1 EA 202192532 A1 EA202192532 A1 EA 202192532A1 EA 202192532 A EA202192532 A EA 202192532A EA 202192532 A EA202192532 A EA 202192532A EA 202192532 A1 EA202192532 A1 EA 202192532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
crohn
mirikizumab
antibody
Prior art date
Application number
EA202192532A
Other languages
English (en)
Russian (ru)
Inventor
Стюарт Уильям Фридрих
Пол Фредерик Поллак
Джей Лоуренс Таттл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202192532A1 publication Critical patent/EA202192532A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
EA202192532A 2019-04-22 2020-04-15 Мирикизумаб для применения в способе лечения болезни крона EA202192532A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
EA202192532A1 true EA202192532A1 (ru) 2022-01-21

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192532A EA202192532A1 (ru) 2019-04-22 2020-04-15 Мирикизумаб для применения в способе лечения болезни крона

Country Status (16)

Country Link
US (1) US20220040299A1 (https=)
EP (1) EP3958897A1 (https=)
JP (3) JP7297930B2 (https=)
KR (2) KR102869852B1 (https=)
CN (2) CN113677366A (https=)
AU (2) AU2020263238C1 (https=)
BR (1) BR112021018930A2 (https=)
EA (1) EA202192532A1 (https=)
IL (2) IL286818B2 (https=)
MA (1) MA55756A (https=)
MX (1) MX2021012848A (https=)
SG (1) SG11202110619XA (https=)
TW (2) TW202515610A (https=)
UA (1) UA128657C2 (https=)
WO (1) WO2020219314A1 (https=)
ZA (1) ZA202108094B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
CA3068673A1 (en) * 2017-07-10 2019-01-17 Rambam Med-Tech Ltd. Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
JP2025148449A (ja) 2025-10-07
KR20210142704A (ko) 2021-11-25
IL324048A (en) 2025-12-01
MX2021012848A (es) 2021-12-10
JP7761614B2 (ja) 2025-10-28
JP2022530397A (ja) 2022-06-29
AU2020263238A1 (en) 2021-11-04
NZ781127A (en) 2025-06-27
CN119700968A (zh) 2025-03-28
MA55756A (fr) 2022-03-02
ZA202108094B (en) 2025-05-28
IL286818B2 (en) 2026-03-01
AU2020263238B2 (en) 2023-08-17
AU2023265759A1 (en) 2023-12-07
IL286818B1 (en) 2025-11-01
IL286818A (en) 2021-10-31
CA3134587A1 (en) 2020-10-29
SG11202110619XA (en) 2021-11-29
CN113677366A (zh) 2021-11-19
JP7297930B2 (ja) 2023-06-26
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
WO2020219314A1 (en) 2020-10-29
KR20250153865A (ko) 2025-10-27
EP3958897A1 (en) 2022-03-02
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
TW202515610A (zh) 2025-04-16
BR112021018930A2 (pt) 2022-01-18
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
AU2020263238C1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
EP3765522A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
WO2018075692A3 (en) Antibody constructs
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
ECSP18010616A (es) Inmunoconjugados de il22
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EP3947466A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA202190504A1 (ru) Способы лечения псориаза
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов